main image

Nanosyn and The Leukemia & Lymphoma Society Announce Achieving a Significant Milestone in Developing New Therapies for MLL Leukemia

Santa Clara, California, April 14, 2015

Nanosyn, Inc. and The Leukemia & Lymphoma Society (LLS) announced today that they have reached important milestones in developing small molecule drug candidates for MLL leukemia, an extremely aggressive type of leukemia that accounts for about 15% of pediatric acute leukemia cases and has the poorest prognosis of any acute leukemia. Nanosyn scientists worked closely with the distinguished academic researchers at University of Michigan, recipients of more than $8 million in LLS funding to support the project.

  • Several small molecule inhibitors that block Menin-MLL fusion interaction (a complex protein-protein interaction) have been advanced to pre-clinical development.
  • The program has been licensed to Kura Oncology, a newly formed biotechnology company that will work on the pre-clinical and clinical development of these drug candidates.  


"We are proud to be part of this program and extremely grateful to LLS for providing an opportunity to work on this challenging project", said Olga Issakova, Ph.D., Executive Vice President of Nanosyn, Inc. "We are delighted to have achieved this important milestone and once again demonstrate the value that we bring to our partnership with LLS".
 
"We deeply appreciate Nanosyn's commitment and skill applied, along with the research group at the University of Michigan, to drug this difficult target," said Lee Greenberger, Ph.D., LLS's Chief Scientific Officer. "New effective therapies for pediatric and adult patient with MLL mutations would clearly have a major impact and is sorely needed."

Last month, Kura Oncology and the University of Michigan announced they entered into a licensing agreement with the goal of bringing these compounds into the clinic.

About Nanosyn
Nanosyn (www.nanosyn.com) is a Contract Research Organization providing integrated drug discovery and development services, medicinal chemistry, made-to-order focused compound libraries, lead optimization, assay development, screening and profiling services, process chemistry, and other innovative solutions to meet our partners' drug discovery needs. Founded in 1998, Nanosyn is a privately held and self-sustaining team of expert scientists. The company is headquartered in the San Francisco Bay Area, California with discovery site in Santa Clara, CA and cGMP kilo lab in Santa Rosa, CA. For inquiries and additional information, contact Olga Issakova, Ph.D., Executive Vice President, at 650-269-3528 to learn more.

About Leukemia and Lymphoma Society
The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, multiple myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world, provides free information and support services, and is the voice for all blood cancer patients seeking access to quality, affordable, coordinated care.
Founded in 1949 and headquartered in White Plains, NY, LLS has chapters throughout the United States and Canada. To learn more, visit www.LLS.org. Patients should contact the Information Resource Center at (800) 955-4572, Monday through Friday, 9 a.m. to 9 p.m. ET.

Nanosyn on Facebook Nanosyn on Twitter Nanosyn on LinkedIn